Next Article in Journal
Influence of the Properties of Different Types of Recycled Aggregate on the Service Properties and Leaching of Paving Blocks Manufactured at Industrial Scale
Next Article in Special Issue
Photothermal Antibacterial and Osteoinductive Polypyrrole@Cu Implants for Biological Tissue Replacement
Previous Article in Journal
New-Generation Materials for Hydrogen Storage in Medium-Entropy Alloys
Previous Article in Special Issue
Epoxidized Soybean Oleic Acid/Oligomeric Poly(lactic acid)-Grafted Nano-Hydroxyapatite and Its Role as a Filler in Poly(L-lactide) for Potential Bone Fixation Application
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Transition-Metal-Oxide-Based Nanozymes for Antitumor Applications

School of Pharmacy, Changzhou University, Changzhou 213164, China
*
Authors to whom correspondence should be addressed.
Materials 2024, 17(12), 2896; https://doi.org/10.3390/ma17122896
Submission received: 17 April 2024 / Revised: 19 May 2024 / Accepted: 20 May 2024 / Published: 13 June 2024
(This article belongs to the Special Issue Advanced Functional Nanomaterials for Biomedical Application)

Abstract

:
Transition metal oxide (TMO)-based nanozymes have appeared as hopeful tools for antitumor applications due to their unique catalytic properties and ability to modulate the tumor microenvironment (TME). The purpose of this review is to provide an overview of the latest progress made in the field of TMO-based nanozymes, focusing on their enzymatic activities and participating metal ions. These nanozymes exhibit catalase (CAT)-, peroxidase (POD)-, superoxide dismutase (SOD)-, oxidase (OXD)-, and glutathione oxidase (GSH-OXD)-like activities, enabling them to regulate reactive oxygen species (ROS) levels and glutathione (GSH) concentrations within the TME. Widely studied transition metals in TMO-based nanozymes include Fe, Mn, Cu, Ce, and the hybrid multimetallic oxides, which are also summarized. The review highlights several innovative nanozyme designs and their multifunctional capabilities. Despite the significant progress in TMO-based nanozymes, challenges such as long-term biosafety, targeting precision, catalytic mechanisms, and theoretical supports remain to be addressed, and these are also discussed. This review contributes to the summary and understanding of the rapid development of TMO-based nanozymes, which holds great promise for advancing nanomedicine and improving cancer treatment.

Graphical Abstract

1. Introduction

Cancer continues to be a significant global public health issue and is currently the second most common cause of death worldwide [1]. Chemotherapy [2], radiotherapy [3,4], surgical resection, and immunotherapy [5] are the four most widely used methods in the treatment of malignant tumors. Although these methods can temporarily address cancer, their effectiveness is coupled with a reduction in the quality of life of cancer patients and a substantial increase in the cost of living. To address this problem and achieve better cancer treatment, many newly developed approaches have emerged in addition to the current main modalities of surgery, chemotherapy, and radiotherapy.
Photothermal therapy (PTT) [6,7], photodynamic therapy (PDT) [8,9,10], sonodynamic therapy (SDT) [11,12] and chemodynamic therapy (CDT) [13,14,15] have been gradually applied to anti-tumor treatment. The tumor microenvironment (TME) creates a favorable environment for tumor growth, proliferation, and metastasis due to factors such as mild acidity [2,16,17], adenosine triphosphate (ATP), the overproduction of H2O2 and antioxidants [18,19,20], hypoxia, and low catalase activity [21]. However, these factors also pose significant challenges to achieving selective and effective tumor treatments. For instance, tumor hypoxia can stimulate the activation of antioxidant enzymes and elevate intracellular redox glutathione (GSH) and antioxidant defense [21,22]. Consequently, it leads to a substantial decrease in the levels of reactive oxygen species (ROS), resulting in resistance to different therapeutic approaches, including ROS-related cancer therapy. Therefore, changing the tumor hypoxic environment, consuming excessive GSH, and increasing the ROS level in the tumor environment have become feasible approaches to tumor inhibition.

2. Nanozymes

Following a report by Gao et al. in 2007 regarding the peroxidase (POD)-like activity of Fe3O4 nanoparticles [23], the investigation of nanozymes as a group of nanomaterials with enzymatic properties has emerged as a rapidly growing field. Artificial enzymes have attracted more attention due to their unique advantages, such as good stability, high catalytic activity, and easy preparation/purification compared with natural enzymes [24,25,26,27]. Nanozymes are defined as “nanomaterials with enzyme-like properties”. Nanozymes have the potential to overcome the drawbacks of natural enzymes, such as instability, high expenses, and challenging storage conditions, and are gradually applied in many fields such as biomedical sensing, diagnosis and treatment, and environmental protection [24]. Compared with traditional anticancer drugs, nanomedicine mainly has the following advantages: improvement in the stability of the drug in vivo, thereby reducing the drug dosage and improving the therapeutic effect; precise therapy through active/passive targeting; reduction in the blocking effect of the physiological barrier and the prolongation of the circulation time of the drug in the body; and the facilitation of controlled drug release in vivo by constructing stimulus–response nanosystems, achieving multi-function and integrated diagnosis and treatment [28]. The unique properties of nanomaterials and the catalytic activity of natural enzymes endow nanozymes with the potential to participate in reactive oxygen species (ROS) generation and cancer therapy [29,30]. Transition-metal-based nanozymes were the first nanozymes to be identified and have attracted increasing interests as therapeutic candidates due to their excellent catalytic properties [31]. They can be classified as metal, metal oxide, metal-organic framework (MOF) [32,33], or hybrid nanozymes [34]. These transition-metal-based nanozymes have a variety of anti-tumor, anti-infective, and anti-inflammatory activities and are expected to be used as potential adjuvants, in adjuvant therapy, or as alternatives to cytotoxic chemotherapy drugs, antibiotics, and non-steroidal anti-inflammatory drugs [35,36,37].
Most nanozymes exhibit the properties of mimetic CAT or POD, which can either convert hydrogen peroxide (H2O2) into highly cytotoxic •OH to eliminate cancer cells or convert it into oxygen to enhance the hypoxic environment of tumors [38,39]. Unfortunately, the catalytic efficiency of these nanozymes is hindered by the highly intricate TME, which poses a significant challenge in achieving the intended therapeutic outcomes [40,41]. From this perspective, the intrinsic reactivity and specific regulatory systems of TME should be explored for effective anticancer therapies. Recently, multivalent metal nanozymes have been extensively explored to simultaneously enhance •OH production and reduce GSH overexpression [42,43]. The construction of multifunctional nanozymes is considered an ideal strategy to induce a variety of intratumoral responses that can be used for selective and efficient tumor therapy [44,45] (Figure 1).

3. Enzymatic Activities of Nanozymes

In recent years, nanozymes have been reported to exhibit a variety of enzymatic activities, which can decompose H2O2 into highly toxic •OH, or O2, or mimic glutathione peroxidase-like activity to consume glutathione in the TME, thus exerting anti-tumor effects [46,47,48,49]. The most frequently reported enzymatic activities are reviewed below.

3.1. Peroxidase (POD)-Mimicking Activity

POD catalyzes the generation of highly cytotoxic hydroxyl radicals (•OH) from hydrogen peroxide (H2O2) in the TME, showing promise in inhibiting tumor growth [50]. The POD-like activity of nanozymes was detected using 3,3’,5,5’-tetramethylbenzidine (TMB), which was oxidized by the produced •OH. And a characteristic peak of oxTMB at 652 nm could be observed. Xie et al. [51] designed a multifunctional metal nanocomposite (PNBCTER) that integrates enzyme catalysis, photodynamic therapy (PDT), photothermal therapy (PTT), chemodynamic therapy (CDT), and immunotherapy for targeted cancer therapy (Figure 2a). The catalytic kinetics of the nanozyme were evaluated using a colorimetric reaction (TMB to oxTMB), and the Km and Vmax values were determined to be 4.66 mM and 1.54 × 10−8 Ms−1, respectively (Figure 2b). Zhang et al. [52] designed a nanozyme probe (AP-HAI) with high efficiency against lung cancer (Figure 2c). Enzymes, after modification by human serum albumin nanoparticles (AP-H), demonstrate excellent POD-like performance (Figure 2d). The Km and the Vmax values were 19.65 μM and 7.676 × 10−8 Ms−1 (Figure 2e). Zhu et al. [53] prepared a well-dispersed MnOOH nanocatalyst. It exhibits good POD enzymatic activity, thereby inhibiting tumor growth. MnOOH also exhibits CAT enzyme-like activity to catabolize H2O2 supplement O2 to regulate TME and catalyze GSH autooxidation.

3.2. Catalase (CAT)-Mimicking Activity

CAT or CAT mimics have the ability to catalyze the decomposition of two H2O2 molecules to generate O2 and H2O, thereby preventing the accumulation of H2O2 and protecting organisms from oxidative damage caused by H2O2 [54,55]. Some nanomaterial-based nanozymes, such as transition metal oxide and multi-metal doped nanozymes, have been found to exhibit CAT-mimetic activity, causing H2O2 decomposition and continuous O2 production in tumor cells to regulate the hypoxic TME. Fu et al. [56] reported a novel CoO@AuPt nanocatalyst with multiple enzymatic activities, including POD, CAT, and oxidase (OXD) activities, to initiate intracellular hemodynamic responses in response to TME (Figure 3a). CAT-like enzyme activity was the most significant. The dissolved oxygen content was determined to rise from a concentration of 10 mg/L to 30 mg/L within 3 min, and the rate of oxygen generation was not significantly correlated with acidity (Figure 3b). Pan et al. [57] designed a bimetal ion-modified MOF nanozyme (Zr4+-MOF-Ru3+/Pt4+-Ce6@HA, ZMRPC@HA). ZMRPC@HA exhibits CAT-mimetic activity and can effectively regulate TME (Figure 3c). When the concentration of ZMRP was 80 μg/mL, the dissolved O2 in the solution significantly increased to 7.47 mg L−1 within 10 min compared with the control group (Figure 3d). In addition, ZMRPC@HA exhibits some POD enzymatic activity and glutathione oxidase (GSH-OXD)-mimetic activity, making it capable of producing toxic ROS and consuming GSH.

3.3. Glutathione Oxidase (GSH-OXD)-Mimicking Activity

Glutathione, the major reducing small molecule in cells, exists in the form of free thiols, which can produce a highly reducing TME and protect cells from free-radical-induced oxidative damage. A widely used strategy to reduce intratumoral GSH levels is to convert the generated glutathione into glutathione disulfide (GSSG) through redox reactions [58]. Meng et al. [59] reported a high-performance pyrite nanozyme (FeS2) with glutathione-oxidase-like activity, which can oxidize glutathione to GSSG and H2O2 (Figure 4a). The pyrite nanozyme catalytic oxidation of reduced glutathione maximum velocity (Vmax) and Michaelis constant (Km) were 0.98 μMs−1 and 0.66 mM (Figure 4b). Moreover, the oxidation of GSH was further enhanced in an oxygen (O2) atmosphere and was inhibited in a nitrogen (N2) atmosphere (Figure 4c), indicating that O2 was involved in this reaction. Pyrite nanozymes also possessed POD-like enzyme activity. Yang et al. [60] designed a hollow mesoporous CuSe/CoSe2@syrosingopine (CSC@Syro) heterostructure as a multifunctional nanoadjuvant for the co-activation of TME and near infrared (NIR) waves (Figure 4d). Due to the presence of Cu+/Cu2+ and Co2+/Co3+ redox couplings, excess GSH can be consumed and further decompose endogenous H2O2 into •OH, resulting in potent ferroptosis. CSC has strong GSH-OXD activity, and 50 µg/mL CSC can completely consume 10 mM GSH in 30 min (Figure 4e).

3.4. Superoxide Dismutase (SOD)-Mimicking Activity

As a key antioxidant enzyme against ROS in cells, SOD catalyzes the dismutation reaction of O2−• to generate O2 and H2O2. Therefore, SOD mimics can be used as a potential drug for the treatment of a variety of oxidative stress diseases [50]. 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-dithiophenyl)-2H-tetrazole) (WST-1), which can interact with O2−•, was used to study the ability of the nanozyme to consume O2−•, The formation of methazalazine showed a special absorption peak at 450 nm. Feng et al. [29]. reported a 2D vanadium carbide (V2C) MXene nanozyme with endogenous enzyme-like activity, such as SOD-enzyme-like activity, which can effectively catalyze O2−• into H2O2 and O2. Notably, the amount of formazan was significantly reduced with increasing V2C MXenzyme concentration, with an inhibition efficiency of 50% at 200 μg/mL V2C MXenzyme. Meanwhile, V2C MXenzyme can also mimic five other naturally occurring enzymes, including CAT, POD, GSH-OXD, thiol peroxidase (TPx), and fluoroperoxidase (HPO). Wang et al. [61] created Ru38Pd34Ni28 ultrathin trimetal nanosheets (TMNSs) by incorporating various transition metal atoms into the RuPd nanosheet structure (Figure 5a). TMNSs possess significant CAT- and SOD-like nanozyme activities (Figure 5b,c). The study found that the amount of O2 generated was directly proportional to the concentration of both TMNSs and H2O2, indicating the exceptional CAT-like activity of TMNSs in effectively removing H2O2 (Figure 5e). Moreover, when the concentration was 25 μg/mL, the inhibition rate was close to 100% (Figure 5d). Under normal physiological conditions, cerium oxide nanozymes have properties similar to SOD and CAT, which have been explored as antioxidants to alleviate a wide range of types of oxidative stress [62]. Gao et al. [63] developed a pH-responsive “oxidative cycle accelerator” using a black phosphorus/cerium catalytic nanozyme (BP@CeO2-PEG) that can be tuned to alleviate acute kidney injury (AKI) induced by platinum compounds (DDP). The nanozyme promotes ATP synthesis and increases the Ce3+/Ce4+ ratio to effectively scavenge ROS in a sustained manner. The BP@CeO2-PEG nanozymes exhibited remarkable SOD-like activity, as evidenced by an inhibition rate of almost 40% at a concentration of 80 μg/mL. BP@CeO2-PEG also has CAT and hydroxyl radical antioxidant capacity (HORAC).

4. Transition Metal Oxide Nanozymes

Transition metal oxides (TMOs) have emerged as one of the most extensively studied classes of transition-metal-based nanozymes due to their unique properties and diverse applications. TMOs exhibit diverse catalytic activities, including OXD-like, POD-like, and SOD-like activities, making them promising candidates for various applications in biomedicine, biosensing, and environmental remediation. The unique physicochemical properties of TMOs, such as their morphology, tunable composition, and surface chemistry, allow for precise control over their catalytic performance. Additionally, TMOs possess inherent stability and durability, making them suitable for practical applications under harsh conditions. Their catalytic mechanisms involve the redox reactions of transition metal ions and the generation of ROS, which facilitate the conversion of substrates into desired products. The development of TMO-based nanozymes, including Fe, Mn, Cu, Ce, and hybrid metals, are reviewed.

4.1. Iron

Fe3O4 nanoparticles (NPs) were the first to be reported to possess POD-like activity, which proved that Fe3O4 NPs are strong candidates for the preparation of nanozymes. Inspired by this pioneering work, POD mimics have been extensively explored and studied, such as Fe3O4 (magnetite), Fe2O3 (hematite), and doped ferrites [64]. Iron-based nanomaterials can also be used as T2-weighted MRI contrast agents [65]. Qin et al. [66] developed UF@PPDF NPs, which are multilayer Fe2O3 structures created by modifying an ultra-small γ-Fe2O3 nanocrystal assembly with folic acid (FA) targeting groups and the chemotherapeutic drug doxorubicin (Figure 6a). The production of •OH was verified using electron paramagnetic resonance (EPR) spectroscopy, with 5, 5-dimethyl-1-pyrroline-N-oxide (DMPO) utilized as the •OH-trapping agent (Figure 6c). Additionally, a lighter color of methylene blue was observed, providing further evidence of •OH generation (Figure 6d). The involvement of GSH was verified by observing a gradual decrease in the absorption of the GSH probe 5,5’-dithiobis-(2-nitrobenzoic acid) (DTNB) over time (Figure 6e). These effects induce ferroptosis in tumor cells in a synergistic manner (Figure 6b). Wang et al. [67] reported an iron engineering framework for mesoporous silica nanoparticles (MSNs) to create a biodegradable and catalytic nanocatalyst (rFeOx-HMSN) with a superferromagnetic framework and T2-MRI properties via a “dissolving regeneration” strategy (Figure 6f). rFeOx-HMSN nanocatalysts can trigger the Fenton reaction in situ, which generates highly toxic hydroxyl radicals to kill cancer cells (Figure 6i). The Lineweaver–Burke plot was utilized to determine the Menten constant Km and maximum velocity Vmax, resulting in Km values of 29.57 mM and 31.43 mM for rFeOx-HMSN nanocatalysts when exposed to 0.8 mM and 1.6 mM TMB, respectively. The rFeOx-HMSN nanocatalyst displayed a maximum •OH radical production rate of 14.272 nM s−1 when exposed to 0.8 mM TMB, while this rate increased to 49.312 nM s−1 when exposed to 1.6 mM TMB (Figure 6g,h). The PEG/rFeOx-HMSN nanocatalyst exhibited a negative MR imaging performance and was observed to accumulate within the tumor tissue. This led to a notable reduction in the T2-weighted negative MRI signal in the tumor tissue. This effect is likely due to the enhanced permeability and retention (EPR) effect, as demonstrated by the circled region in the MR images (Figure 6j). Mao et al. [68] designed and constructed a smart nano-catalytic platform, the DMSN-Au-Fe3O4 NP, which for the first time took advantage of the unique catalytic activity of Au NPs co-modified on dendritic mesoporous silica NPs mimicking glucose oxidase (GOx) and the POD of Fe3O4 NPs. It catalyzed the TME response cascade and promoted the production of H2O2 and ROS.

4.2. Manganese

Compared with Cr, Co, and other elements with high biological toxicity, Mn is a natural and non-toxic element, making it a more appropriate choice for use in biological applications [69]. Manganese-based nanomaterials, including manganese dioxide (MnO2) and manganese tetroxide (Mn3O4), have the advantages of better response to TME, wider pH range [70], and closer radius to Fe. It can also use its own Fenton effect to catalyze H2O2 to produce toxic •OH, which can be used for anti-tumor applications [71]. MnO2 has the ability to act as a catalyst for the decomposition of hydrogen peroxide (H2O2) to generate oxygen. Due to its properties as an inorganic nanozyme, MnO2 has significant potential for use in multifunctional nanomaterials designed for cancer therapy [72,73]. In addition, MnO2 reacts with GSH to form Mn2+, which can be used for magnetic resonance imaging (MRI) [74,75]. Xu et al. [76] developed a nanoplatform called the Ce6/MnO2@DPC NP (DPCCM NP) that is responsive to changes in pH and the presence of hydrogen peroxide (H2O2). This nanoplatform exhibits exceptional CAT enzyme activity and possesses various functions that enhance cellular uptake, stimulate oxygen generation, and improve the efficacy of PDT (Figure 7a). Lin et al. [70] reported a self-strengthening CDT nanoagent (MS@MnO2), which has the ability to deliver Mn2+ in a Fenton-like manner and deplete glutathione (GSH). This nanoagent acts as an intelligent chemokinetic agent that disrupts cellular antioxidant defense systems (ADS) and supplies cells with •OH producers, ultimately resulting in enhanced cancer cell death through CDT (Figure 7b,c). Due to the presence of Mn2+, MS@MnO2 can be used for combined tumor therapy under magnetic resonance imaging (MRI) monitoring.
Compared to copper zinc superoxide dismutase (Cu/Zn SOD) and iron superoxide dismutase (Fe SOD), natural manganese superoxide dismutase (Mn SOD) has shown superior efficacy in treating chronic diseases. This has motivated researchers to work on synthesizing SOD based on manganese, with the goal of developing more effective treatments for these conditions [77]. Yao et al. [78] demonstrated that Mn3O4 NPs synthesized by hydrothermal method had significant SOD-like enzyme activities and CAT-like enzyme activities as well as hydroxyl radical scavenging activity due to the dual oxidation state of Mn2+ and Mn3+. At a concentration of 20 mg/mL of Mn3O4 NPs, the removal efficiency of O2−• was approximately 75%, and that of H2O2 was about 75%, which was even more efficient than that of 10 U mL−1 CAT. Huang et al. [79] synthesized UiO-66(Hf)-NH2 and then coated Mn3O4 particles in it, resulting in a core–shell structure named UiO@Mn3O4 (UM) (Figure 7d). The gradual disappearance of the yellow color of TNB with increases in the concentration of UM, as depicted in Figure 7e, suggests that UM fully consumed GSH. Subsequently, the Mn2+-mediated Fenton-like reaction was investigated (Figure 7f). In Figure 7g, it can be observed that UM treated with GSH displayed paramagnetic characteristics, with an r1 value of 8.20 mM−1 s−1. Additionally, the T1-field MRI signal increased gradually as the concentration of UM increased. The UiO@Mn3O4@PAA (UMP) nanocomposite was found to be an effective nanoregulator for relieving hypoxia and inducing oxidative stress through the Fenton-like reaction, which was enhanced by GSH depletion. UMP exhibited excellent efficacy in eliminating primary, distant, and metastatic tumors (Figure 7h).
Figure 7. (a) Synthesis of DPCCM NPs and their application in pH/H2O2–responsive enhanced photodynamic therapy [76]. (b) The mechanism of MnO2 as a smart chemodynamic agent for enhanced CDT for cancer. (c) Illustration of the application of MS@MnO2 NPs for MRI-monitored chemodynamic combination therapy [70]. (d) Illustration of multiple strategies for immunogenic radiotherapy for UMP. (e) The absorption spectra of DTNB in the UV–Vis range after its degradation by GSH treated with varying concentrations of UM. Inset: the corresponding photo. (f) The absorption spectra of MB in the UV–Vis range after degradation by H2O2 and GSH-treated UM. Inset: the corresponding photo. (g) T1-weighted MR images of UM solution containing varying concentrations of Mn (0, 0.1, 0.25, 0.5, 0.75, and 1 mM) with or without 10 mM GSH treatment. (h) Images of the primary tumors and their corresponding weights obtained from different groups on the 16th day [79].
Figure 7. (a) Synthesis of DPCCM NPs and their application in pH/H2O2–responsive enhanced photodynamic therapy [76]. (b) The mechanism of MnO2 as a smart chemodynamic agent for enhanced CDT for cancer. (c) Illustration of the application of MS@MnO2 NPs for MRI-monitored chemodynamic combination therapy [70]. (d) Illustration of multiple strategies for immunogenic radiotherapy for UMP. (e) The absorption spectra of DTNB in the UV–Vis range after its degradation by GSH treated with varying concentrations of UM. Inset: the corresponding photo. (f) The absorption spectra of MB in the UV–Vis range after degradation by H2O2 and GSH-treated UM. Inset: the corresponding photo. (g) T1-weighted MR images of UM solution containing varying concentrations of Mn (0, 0.1, 0.25, 0.5, 0.75, and 1 mM) with or without 10 mM GSH treatment. (h) Images of the primary tumors and their corresponding weights obtained from different groups on the 16th day [79].
Materials 17 02896 g007

4.3. Copper

Copper-based nanomaterials, such as copper nanoparticles (Cu NPs), copper sulfide (CuS), copper selenide (Cu2Se), copper oxide (CuO), etc., have high photothermal conversion rates, and they can catalyze H2O2 in TME to produce excess •OH, which reshapes the TME and induces the death of tumor cells [80,81]. Cuprous oxide (Cu2O), as a stable copper-based nanomedicine, has been confirmed to promote tumor cell apoptosis by producing ROS in melanoma, bladder cancer, and cervical cancer cell lines [82,83]. Wang et al. [84]. constructed a bifunctional nanocatalyst called Cu2O@Dex, which was composed of dextran. This nanocatalyst has the ability to restore normal tumor perfusion and oxygenation in a straightforward manner. Through pH-sensitive dual catalytic functions, Cu2O@Dex generates both nitric oxide (NO) and •OH simultaneously. Under weakly acidic conditions (pH 6.5), the release of Cu (Cu+/2+) from Cu2O@Dex initiates the catalytic process, leading to the production of NO and subsequent vascular normalization. In addition, Cu2O@Dex further released a mass of Cu (Cu+/2+) under more acidic intratumoral cells (pH 5.5), which rapidly catalyzed •OH generation and enhanced CDT efficacy. Since copper is an essential trace element in the human body and is involved in the functioning of various enzymes, including tyrosinase and Cu-Zn SOD [85,86], it is logical to assume that copper-based nanomaterials can be utilized to eliminate ROS. Liu and colleagues [87] demonstrated the straightforward and effective one-step synthesis of ultra-small Cu5.4O NPs (Cu5.4O USNPs) that exhibit diverse enzyme-like properties and a wide range of ROS scavenging capabilities for the treatment of ROS-related diseases. These Cu5.4O USNPs not only function as CAT, SOD, and GSH-OXD mimics but also showed protective effects against ROS-induced damage at very low concentrations, leading to significantly improved therapeutic outcomes in conditions such as acute liver injury, acute kidney injury, and wound healing. Meng et al. [88] created dual-shell structures consisting of hollow cuprous oxide and nitrogen-doped carbon (HCONC) (Figure 8a). These structures were specifically designed to serve as nanozymes for oncotherapy through CDT (Figure 8a,b). The Fenton-like reaction mediated by Cu+ can effectively break down H2O2 to produce •OH under relatively mild conditions. In comparison to SCONC, the colorimetric reaction and the ability to generate •OH between TMB and HCONC were more pronounced and rapid (Figure 8c,d). Both SCONC and HCONC showed Michaelis–Menten and Lineweaver–Burke plots, but the •OH generation activity of HCONC was significantly greater than that of SCONC (Figure 8e).

4.4. Cerium

The exceptional catalytic activity of CeO2 nanozymes has led to significant advancements in cancer treatment [89,90]. The rapid conversion between Ce3+ and Ce4+ results in the generation of oxygen vacancies on the surface of CeO2, which determines the POD and OXD activities of CeO2 [91,92,93]. Cheng et al. [94] designed a stable nanocomposite material (CeO2/Y) modified by highly dispersed CeO2 nanoparticles on Y-type zeolite as a carrier and synthesized the CeO2/Y nanocomposite material through a simple wet impregnation method. CeO2/Y nanocomposites were also proposed for the first time as an efficient POD-mimicking nanozyme for the accurate detection of H2O2 and glucose. Using this POD-like activity, Cheng and colleagues [95] constructed a novel anti-tumor controlled release system (Cu-CeO2 NPs) loaded with breast cancer cell membrane and the clinical anticancer drug DOX for cancer treatment (Figure 9a). The addition of copper ions to the CeO2 nanozymes resulted in a significant increase in the Ce3+/Ce4+ ratio, leading to a significant improvement in the POD-like activity of the TME-specific cancer therapy drug. To test the ROS scavenging ability of CeO2 NPs under physiological conditions, H2O2 was used as the most prevalent type of ROS. The complete removal of H2O2 was observed within 5 h of the introduction of Co-CeO2, Mn-CeO2, and Cu-CeO2 NPs, indicating a significantly higher catalytic efficiency compared to other types of CeO2-based nanoparticles (Figure 9b,c). Through the implementation of site-selective growth and steric restriction strategies, Ma et al. [96] developed a distinctive pushpin-shaped Au/CeO2 hybrid nanozyme that exhibits exceptional catalytic activity. Au/CeO2 has superior catalytic activity and targeting ability and exhibits a good anti-tumor effect in vitro and in vivo.

4.5. Multimetallic Oxide

Recently, the distinctive biological, physical, and chemical properties of transition-metal-based nanomaterials upon entering tumor cells, known as biological effects, have garnered significant attention [97]. The significance of metal ions and metal-based nanomaterials in cancer treatment cannot be overstated, as demonstrated by the various roles they play. For instance, Ca2+ can regulate T cell receptor activation, K+ can control stem cell differentiation, Mn2+ can activate the STING pathway, and Fe2+/3+ can facilitate tumor ferroptosis and augment catalytic therapy [98]. However, the therapeutic effect of a single metal material is limited. Therefore, a growing number of metal composite materials have been designed and applied [99,100]. The cGAS-STING pathway can be activated by Mn2+ and Zn2+, which implies that they possess the capacity to function as immune activators [101,102]. Lei et al. [103] designed the bimetal oxide manganese molybdate nanoparticle MnMoOx-PEG (MMP NDs), which was constructed from Mn2+ and MoO42− and modified by distearoyl phosphatidylethanolamine-polyethylene glycol 5000 (DSPE-PEG5k). The presence of high-valence Mo6+ and Mn4+ in MMP NDs allows for their reduction into a low-valence Mo5+ and Mn2+ by GSH. This is believed to enhance their ability to facilitate ferroptosis. When the incubation time was prolonged, the characteristic UV-Vis absorption peak of DTNB at ~412 nm exhibited a marked decrease, indicating the efficient GSH consumption capacity of MMP NDs. MMP NDs, when administered intravenously, can effectively reverse the immunosuppressive tumor microenvironment (TME), while also facilitating both the initiation and enhancement of cancer immunotherapy (CIT), without requiring any additional immune adjuvants. Zhang et al. [104] introduced a composite nanoenzyme (MnMoOx), obtained by thermally injecting manganese into the molybdenum oxide semiconductor (Figure 10a). The cascade CAT and OXD activity (Figure 10b) were directly influenced by the surface plasmon resonance (SPR) effect. The production of ROS was indirectly confirmed through the UV-Vis absorption spectra and digital photographs of the different groups using TMB as probes, as shown in Figure 10c. The composite was utilized to perform antitumor therapy, which was guided by tri-modal imaging and activated by the tumor microenvironment, while also involving a cascade catalytic process (Figure 10d).
Liu et al. [105] introduced a new biomimetic platform (ZnMnFe2O4–PEG–FA) with both photothermal and catalytic activity for tumor therapy. This platform exhibits excellent photothermal effects, with a photothermal conversion efficiency (η) of approximately 47.8%. Moreover, it demonstrates remarkable POD-like activity, with determined Km and Vmax values of 45.2 mM and 1.62 × 10−7 Ms−1, respectively. The combination of these properties enables synergistic tumor cell diagnosis and ablation. Lv et al. [106] developed a multinanozyme system, known as HA-CuMnOx@ICG nanocomposites (CMOI NCs), by incorporating indocyanine green (ICG) into hyaluronic acid (HA)-stabilized CuMnOx nanoparticles (CMOH) via a straightforward synthesis method (Figure 11a). The CMOI NCs demonstrated enhanced multienzyme catalytic activities, including POD-like, CAT-like (Figure 11b), and OXD-like activities, along with the ability to deplete GSH. These properties, combined with photothermal enhancement, enabled synergistic photothermal therapy and enhanced tumor oxidation.
Figure 10. (a) Schematic diagram of the synthetic process of the MnMoOx NUs. (b) Scheme of the catalytic process (I) and enhanced SPR (II) of MnMoOx NUs. (c) The absorption spectra of TMB and corresponding digital photos of different groups. (d) Illustration of the working mechanisms of the MnMoOx NUs [104].
Figure 10. (a) Schematic diagram of the synthetic process of the MnMoOx NUs. (b) Scheme of the catalytic process (I) and enhanced SPR (II) of MnMoOx NUs. (c) The absorption spectra of TMB and corresponding digital photos of different groups. (d) Illustration of the working mechanisms of the MnMoOx NUs [104].
Materials 17 02896 g010
The presence of multivalent metal ions (Sn2+/Sn4+ and Fe2+/Fe3+) and strong absorption in the NIR region make bimetallic oxides, such as tin ferrite (SnFe2O4, referred to as SFO), highly appealing in the field of photocatalysis. As a result, SFO has garnered significant attentions [107,108,109,110]. Feng et al. [111] proposed a novel TME-regulated nanozyme using tin ferritate (SnFe2O4) for simultaneous PTT, PDT, and CDT (Figure 11c). The presence of Sn2+/Sn4+ and Fe2+/Fe3+ redox coupling enables SFO to exhibit excellent •OH generation capacity through Fenton-like reactions, while eliminating overexpressed GSH in TME and reducing tumor antioxidant capacity through GSH-OXD-like activity (Figure 11d). Importantly, SFO nanozymes can interact with endogenous H2O2 to produce O2, thereby alleviating hypoxia in the TME. Wang et al. [112] synthesized Cu-Co oxide porous carbon nanocomposites (CuCo(O)/GOx@PCNs) loaded with GOx via pyrolysis and the calcination of Cu-doped bilayer MOF (Figure 11e). The hybrid nanozyme system was able to achieve three distinct functions, which included oxygen generation (Figure 11f), glucose consumption, and photothermal conversion, all within a single system. CuCo(O)/GOx@PCNs can enter tumor cells to regulate TME and alleviate hypoxia, achieving the synergistic treatment of starvation therapy and PTT and inducing a systemic immune response to inhibit the growth of distant tumors (Figure 11g). The representative nanozymes with multienzymatic activities for enhancing tumor therapy are selected and listed in Table 1.
Figure 11. (a) Schematic diagram of the synthetic process of the CMOI NCs. (b) O2 generation curves of CMOI NCs aqueous solutions with different concentrations [106]. (c) Schematic illustration for the synthetic process of SFO. (d) Time-dependent GSH depletion by SFO [111]. (e) Fabrication procedure of the CuCo(O)@PCNs nanoenzyme. (f) Comparison of O2 generation of the Co3O4-NCNHS and CuCo(O)@PCNs samples. (g) Schematic illustration of the ZIF-derived nanozyme CuCo(O)@PCNs with three-in-one functions to achieve synergetic therapy [112].
Figure 11. (a) Schematic diagram of the synthetic process of the CMOI NCs. (b) O2 generation curves of CMOI NCs aqueous solutions with different concentrations [106]. (c) Schematic illustration for the synthetic process of SFO. (d) Time-dependent GSH depletion by SFO [111]. (e) Fabrication procedure of the CuCo(O)@PCNs nanoenzyme. (f) Comparison of O2 generation of the Co3O4-NCNHS and CuCo(O)@PCNs samples. (g) Schematic illustration of the ZIF-derived nanozyme CuCo(O)@PCNs with three-in-one functions to achieve synergetic therapy [112].
Materials 17 02896 g011

5. Improvement Strategies and Technologies of Nanozymes

To enhance the potential of nanozymes as substitutes for natural enzymes, researchers must focus on optimizing their specificity and catalytic efficiency through innovative design strategies and advanced fabrication techniques. The activities of nanozymes can be greatly modulated via the regulation of morphology, valence, composition, the architecture of the active sites, and surface modification, which have been universally proven recently. Smaller size or propriate morphology can expose more active sites and elevate catalytic activity of nanozymes by increasing surface-to-volume ratio and facilitating mass transport [113,114,115,116,117]. Surficial coatings of nanozymes via the physisorption of small molecules, ions, and polymers or covalent bonding contribute to their activity adjustment by causing variations in surficial charge and microenvironment [118]. The surface modification of nanomaterials not only acts as a stabilizer in the synthesis of nanomaterials, but also provides a reaction site for the further coupling of functional groups. The catalytic performance is also heavily influenced by the surface valence conditions and the presence of oxygen vacancies within its structure. To enhance the catalytic efficiency of the nanozyme, it is crucial to optimize its structural composition through strategies such as alloying or doping. New strategies have also been proposed to elevate catalytic activity by mimicking the nanostructure of the active sites or the enzymatic microenvironment of natural enzymes.
Besides experimental technique development, computational protocols involving the development of new atomistic force field parameters, flexible docking with Brownian dynamics, and µs-long MD simulations contribute greatly to the microscopic view at the basis of experimental results for nanozymes [119,120]. The computational methodology is beneficial for problem solving, such as tuning the catalytically active sites, as well as designing proper nanostructures with target enzymatic activity in nanomedicine in the future [121,122].
Despite the significant progress made, several obstacles still hinder the further advancement and practical implementation of nanozymes. The large-scale production of nanozymes is easily influenced by reaction conditions, and their catalytic activity and selectivity still need enhancement. While various synthesis methods have been reported, there has been no groundbreaking innovation compared to traditional nanomaterial fabrication techniques. Although some new mechanisms have been reported in the study of nanozymes’ catalytic properties, the precise 3D structure of their active sites remains unknown. However, these challenges can be overcome through persistent efforts and continuous advancements in material science, chemistry, nanoscience, and technology. In addition to experimental work, researchers should also focus on theoretical calculations, which can help reveal new catalytic mechanisms of nanozymes. By combining experimental and computational approaches, we can deepen our understanding of nanozymes toward their widespread use.

6. Limitations

Despite significant progress in the application of TMO-based nanozymes for tumor therapy, several challenges remain to be addressed, which are listed as follows.
(1)
Although many multifunctional nanozymes have demonstrated promising results in vitro, their potential for clinical applications remains uncertain. For example, nanozymes should be designed to be hypersensitive to H2O2 for degradation since the concentration of H2O2 in vivo is around a few micromoles.
(2)
The cytotoxicity and biocompatibility of TMO-based nanozymes has not been fully confirmed, especially for nanomaterials containing transition metals. Further studies are required to investigate the mechanisms and pharmacokinetics of nanozymes based on TMOs before they can be considered for clinical application.
(3)
Nanozymes possessing multiple enzymatic activities have the ability to catalyze a diverse array of substrates. The multifunctional properties of nanozymes could be beneficial for expanding their applications in tumor therapy; however, they may also introduce some adverse factors. It is crucial to enhance the targeting ability of nanozymes and validate their localization. While nanozymes primarily exhibit oxidoreductase or hydrolase activities, there is a need for ongoing exploration and development of other enzyme-mimicking activities to cater to the diverse requirements of tumor treatment. This will enable nanozymes to exhibit a wider range of functions.
(4)
There is a need for more theoretical studies on multifunctional nanozymes in order to combine experimental and computational results and improve our understanding of their underlying principles. The catalytic mechanisms of these nanozymes remain unclear and require further investigation.

7. Conclusions and Prospects

TMO-based nanozymes exhibit excellent catalytic properties, unique photoelectric effects, and variable oxidation states due to the special electronic configuration of transition metal valence electrons. They have been widely developed and applied in biological fields. With the advancement of nanotechnology and a deeper understanding of catalytic mechanisms, the research on TMO-based nanozymes has been boosted. Furthermore, their higher stability and unique physicochemical properties make them highly suitable for biomedical applications. In this paper, we summarized the recent most commonly studied enzymatic activities of nanozymes and representative metallic oxide nanomaterials. Despite significant progress in the biomedical applications of TMO-based nanozymes, potential challenges, uncertainties regarding long-term biosafety, and key technical problems hinder its short-term clinical application.
In summary, the development of TMO-based nanozymes has made rapid progress and has shown broad application prospects in anti-tumor treatments. Although these therapies differ significantly from traditional treatments, their highly active performance and great potential make transition-metal-based nanozymes worthy of in-depth research. This review can provide a promising perspective and broaden the pathways for designing transition-metal-based nanozymes, which may benefit the rapid development of nanomedicine and biomedical materials in the future.

Author Contributions

H.S.: writing—original draft. Y.B.: writing—review and editing. D.Z.: writing—review and editing. J.W.: Conceptualization, writing—review and editing, supervision, funding acquisition. L.Q.: conceptualization, writing—review and editing, supervision. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by the funding from National Key Research and Development Program of China (No. 2023YFE0203500), National Natural Science Foundation of China (No. 22207011, 22375026), Changzhou Leading Innovative Talents Introduction and Cultivation Project (CQ20220085), and Postgraduate Research & Practice Innovation Program of Jiangsu Province (SJCX23_1444).

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics. CA-Cancer J. Clin. 2016, 66, 7–30. [Google Scholar] [CrossRef] [PubMed]
  2. Wu, W.; Yu, L.; Jiang, Q.; Huo, M.; Lin, H.; Wang, L.; Chen, Y.; Shi, J. Enhanced Tumor-Specific Disulfiram Chemotherapy by In Situ Cu2+ Chelation-Initiated Nontoxicity-to-Toxicity Transition. J. Am. Chem. Soc. 2019, 141, 11531–11539. [Google Scholar] [CrossRef] [PubMed]
  3. Qiao, Y.; Yang, F.; Xie, T.; Du, Z.; Zhong, D.; Qi, Y.; Li, Y.; Li, W.; Lu, Z.; Rao, J.; et al. Engineered algae: A novel oxygen-generating system for effective treatment of hypoxic cancer. Sci. Adv. 2020, 6, eaba5996. [Google Scholar] [CrossRef] [PubMed]
  4. Tang, W.; Yang, Z.; He, L.; Deng, L.; Fathi, P.; Zhu, S.; Li, L.; Shen, B.; Wang, Z.; Jacobson, O.; et al. A hybrid semiconducting organosilica-based O2 nanoeconomizer for on-demand synergistic photothermally boosted radiotherapy. Nat. Commun. 2021, 12, 523. [Google Scholar] [CrossRef] [PubMed]
  5. Bai, S.; Jiang, H.; Song, Y.; Zhu, Y.; Qin, M.; He, C.; Du, G.; Sun, X. Aluminum nanoparticles deliver a dual-epitope peptide for enhanced anti-tumor immunotherapy. J. Control. Release 2022, 344, 134–146. [Google Scholar] [CrossRef] [PubMed]
  6. Yu, J.; Yang, C.; Li, J.; Ding, Y.; Zhang, L.; Yousaf, M.Z.; Lin, J.; Pang, R.; Wei, L.; Xu, L.; et al. Multifunctional Fe5C2 Nanoparticles: A Targeted Theranostic Platform for Magnetic Resonance Imaging and Photoacoustic Tomography-Guided Photothermal Therapy. Adv. Mater. 2014, 26, 4114–4120. [Google Scholar] [CrossRef] [PubMed]
  7. Yu, J.; Ju, Y.; Zhao, L.; Chu, X.; Yang, W.; Tian, Y.; Sheng, F.; Lin, J.; Liu, F.; Dong, Y.; et al. Multistimuli-Regulated Photochemothermal Cancer Therapy Remotely Controlled via Fe5C2 Nanoparticles. ACS Nano 2016, 10, 159–169. [Google Scholar] [CrossRef] [PubMed]
  8. Wang, D.; Wu, H.; Yang, G.; Qian, C.; Gu, L.; Wang, H.; Zhou, W.; Liu, J.; Wu, Y.; Zhang, X.; et al. Metal–Organic Framework Derived Multicomponent Nanoagent as a Reactive Oxygen Species Amplifier for Enhanced Photodynamic Therapy. ACS Nano 2020, 14, 13500–13511. [Google Scholar] [CrossRef]
  9. Zhang, Y.; Wang, F.; Liu, C.; Wang, Z.; Kang, L.; Huang, Y.; Dong, K.; Ren, J.; Qu, X. Nanozyme Decorated Metal–Organic Frameworks for Enhanced Photodynamic Therapy. ACS Nano 2018, 12, 651–661. [Google Scholar] [CrossRef] [PubMed]
  10. Wang, D.; Wu, H.; Phua, S.Z.F.; Yang, G.; Qi Lim, W.; Gu, L.; Qian, C.; Wang, H.; Guo, Z.; Chen, H.; et al. Self-assembled single-atom nanozyme for enhanced photodynamic therapy treatment of tumor. Nat. Commun. 2020, 11, 357. [Google Scholar] [CrossRef] [PubMed]
  11. Pan, X.; Wang, W.; Huang, Z.; Liu, S.; Guo, J.; Zhang, F.; Yuan, H.; Li, X.; Liu, F.; Liu, H. MOF-Derived Double-Layer Hollow Nanoparticles with Oxygen Generation Ability for Multimodal Imaging-Guided Sonodynamic Therapy. Angew. Chem. Int. Ed. 2020, 59, 13557–13561. [Google Scholar] [CrossRef] [PubMed]
  12. Hasegawa, S.; Clever, G.H. Metallo-supramolecular Shell Enables Regioselective Multi-functionalization of Fullerenes. Chem 2020, 6, 5–7. [Google Scholar] [CrossRef]
  13. Tian, Q.; Xue, F.; Wang, Y.; Cheng, Y.; An, L.; Yang, S.; Chen, X.; Huang, G. Recent advances in enhanced chemodynamic therapy strategies. Nano Today 2021, 39, 101162. [Google Scholar] [CrossRef]
  14. Li, S.-L.; Jiang, P.; Jiang, F.-L.; Liu, Y. Recent Advances in Nanomaterial-Based Nanoplatforms for Chemodynamic Cancer Therapy. Adv. Funct. Mater. 2021, 31, 2100243. [Google Scholar] [CrossRef]
  15. Huang, Y.; Wu, S.; Zhang, L.; Deng, Q.; Ren, J.; Qu, X. A Metabolic Multistage Glutathione Depletion Used for Tumor-Specific Chemodynamic Therapy. ACS Nano 2022, 16, 4228–4238. [Google Scholar] [CrossRef] [PubMed]
  16. Liu, M.; Huang, L.; Zhang, W.; Wang, X.; Geng, Y.; Zhang, Y.; Wang, L.; Zhang, W.; Zhang, Y.-J.; Xiao, S.; et al. A transistor-like pH-sensitive nanodetergent for selective cancer therapy. Nat. Nanotechnol. 2022, 17, 541–551. [Google Scholar] [CrossRef] [PubMed]
  17. Chen, W.-H.; Yu, X.; Cecconello, A.; Sohn, Y.S.; Nechushtai, R.; Willner, I. Stimuli-responsive nucleic acid-functionalized metal–organic framework nanoparticles using pH- and metal-ion-dependent DNAzymes as locks. Chem. Sci. 2017, 8, 5769–5780. [Google Scholar] [CrossRef] [PubMed]
  18. Liu, J.; Yuan, Y.; Cheng, Y.; Fu, D.; Chen, Z.; Wang, Y.; Zhang, L.; Yao, C.; Shi, L.; Li, M.; et al. Copper-Based Metal–Organic Framework Overcomes Cancer Chemoresistance through Systemically Disrupting Dynamically Balanced Cellular Redox Homeostasis. J. Am. Chem. Soc. 2022, 144, 4799–4809. [Google Scholar] [CrossRef] [PubMed]
  19. Wang, M.; Chang, M.; Li, C.; Chen, Q.; Hou, Z.; Xing, B.; Lin, J. Tumor-Microenvironment-Activated Reactive Oxygen Species Amplifier for Enzymatic Cascade Cancer Starvation/Chemodynamic /Immunotherapy. Adv. Mater. 2022, 34, 2106010. [Google Scholar] [CrossRef] [PubMed]
  20. Chen, W.-H.; Yu, X.; Liao, W.-C.; Sohn, Y.S.; Cecconello, A.; Kozell, A.; Nechushtai, R.; Willner, I. ATP-Responsive Aptamer-Based Metal–Organic Framework Nanoparticles (NMOFs) for the Controlled Release of Loads and Drugs. Adv. Funct. Mater. 2017, 27, 1702102. [Google Scholar] [CrossRef]
  21. Li, Y.; Zhao, P.; Gong, T.; Wang, H.; Jiang, X.; Cheng, H.; Liu, Y.; Wu, Y.; Bu, W. Redox Dyshomeostasis Strategy for Hypoxic Tumor Therapy Based on DNAzyme-Loaded Electrophilic ZIFs. Angew. Chem. Int. Ed. 2020, 59, 22537–22543. [Google Scholar] [CrossRef] [PubMed]
  22. Liu, Y.; Jiang, Y.; Zhang, M.; Tang, Z.; He, M.; Bu, W. Modulating Hypoxia via Nanomaterials Chemistry for Efficient Treatment of Solid Tumors. Acc. Chem. Res. 2018, 51, 2502–2511. [Google Scholar] [CrossRef] [PubMed]
  23. Gao, L.; Zhuang, J.; Nie, L.; Zhang, J.; Zhang, Y.; Gu, N.; Wang, T.; Feng, J.; Yang, D.; Perrett, S.; et al. Intrinsic peroxidase-like activity of ferromagnetic nanoparticles. Nat. Nanotechnol. 2007, 2, 577–583. [Google Scholar] [CrossRef]
  24. Wu, J.; Wang, X.; Wang, Q.; Lou, Z.; Li, S.; Zhu, Y.; Qin, L.; Wei, H. Nanomaterials with enzyme-like characteristics (nanozymes): Next-generation artificial enzymes (II). Chem. Soc. Rev. 2019, 48, 1004–1076. [Google Scholar] [PubMed]
  25. Wang, Q.; Zhang, X.; Huang, L.; Zhang, Z.; Dong, S. GOx@ZIF-8(NiPd) Nanoflower: An Artificial Enzyme System for Tandem Catalysis. Angew. Chem. Int. Ed. 2017, 56, 16082–16085. [Google Scholar] [CrossRef] [PubMed]
  26. Yi, H.; Yan, M.; Huang, D.; Zeng, G.; Lai, C.; Li, M.; Huo, X.; Qin, L.; Liu, S.; Liu, X.; et al. Synergistic effect of artificial enzyme and 2D nano-structured Bi2WO6 for eco-friendly and efficient biomimetic photocatalysis. Appl. Catal. B-Environ. Energy. 2019, 250, 52–62. [Google Scholar] [CrossRef]
  27. Hu, R.; Fang, Y.; Huo, M.; Yao, H.; Wang, C.; Chen, Y.; Wu, R. Ultrasmall Cu2-xS nanodots as photothermal-enhanced Fenton nanocatalysts for synergistic tumor therapy at NIR-II biowindow. Biomaterials 2019, 206, 101–114. [Google Scholar] [CrossRef] [PubMed]
  28. Li, Y.; Guo, Y.; Zhang, K.; Zhu, R.; Chen, X.; Zhang, Z.; Yang, W. Cell Death Pathway Regulation by Functional Nanomedicines for Robust Antitumor Immunity. Adv Mater. 2024, 11, 2306580. [Google Scholar] [CrossRef] [PubMed]
  29. Feng, W.; Han, X.; Hu, H.; Chang, M.; Ding, L.; Xiang, H.; Chen, Y.; Li, Y. 2D vanadium carbide MXenzyme to alleviate ROS-mediated inflammatory and neurodegenerative diseases. Nat. Commun. 2021, 12, 2203. [Google Scholar] [CrossRef] [PubMed]
  30. Xu, B.; Li, S.; Zheng, L.; Liu, Y.; Han, A.; Zhang, J.; Huang, Z.; Xie, H.; Fan, K.; Gao, L.; et al. A Bioinspired Five-Coordinated Single-Atom Iron Nanozyme for Tumor Catalytic Therapy. Adv. Mater. 2022, 34, 2107088. [Google Scholar] [CrossRef] [PubMed]
  31. Robert, A.; Meunier, B. How to Define a Nanozyme. ACS Nano 2022, 16, 6956–6959. [Google Scholar] [CrossRef] [PubMed]
  32. Liu, C.; Bai, Y.; Li, W.; Yang, F.; Zhang, G.; Pang, H. In Situ Growth of Three-Dimensional MXene/Metal–Organic Framework Composites for High-Performance Supercapacitors. Angew. Chem. Int. Ed. 2022, 61, e202116282. [Google Scholar] [CrossRef] [PubMed]
  33. Chen, T.; Wang, F.; Cao, S.; Bai, Y.; Zheng, S.; Li, W.; Zhang, S.; Hu, S.-X.; Pang, H. In Situ Synthesis of MOF-74 Family for High Areal Energy Density of Aqueous Nickel–Zinc Batteries. Adv. Mater. 2022, 34, 2201779. [Google Scholar] [CrossRef]
  34. Xie, S.-Y.; Li, X.-B. Metallic Graphene Nanoribbons. Nano-Micro Lett. 2021, 13, 53. [Google Scholar] [CrossRef]
  35. Xing, L.; Liu, X.-Y.; Zhou, T.-J.; Wan, X.; Wang, Y.; Jiang, H.-L. Photothermal nanozyme-ignited Fenton reaction-independent ferroptosis for breast cancer therapy. J. Control. Release 2021, 339, 14–26. [Google Scholar] [CrossRef] [PubMed]
  36. Niu, R.; Liu, Y.; Wang, Y.; Zhang, H. An Fe-based single-atom nanozyme with multi-enzyme activity for parallel catalytic therapy via a cascade reaction. Chem. Commun. 2022, 58, 7924–7927. [Google Scholar] [CrossRef]
  37. Huang, Y.; Liu, Z.; Liu, C.; Ju, E.; Zhang, Y.; Ren, J.; Qu, X. Self-Assembly of Multi-nanozymes to Mimic an Intracellular Antioxidant Defense System. Angew. Chem. Int. Ed. 2016, 55, 6646–6650. [Google Scholar] [CrossRef] [PubMed]
  38. Wang, L.; Gao, F.; Wang, A.; Chen, X.; Li, H.; Zhang, X.; Zheng, H.; Ji, R.; Li, B.; Yu, X.; et al. Defect-Rich Adhesive Molybdenum Disulfide/rGO Vertical Heterostructures with Enhanced Nanozyme Activity for Smart Bacterial Killing Application. Adv. Mater. 2020, 32, 2005423. [Google Scholar] [CrossRef] [PubMed]
  39. Liang, H.; Lin, F.; Zhang, Z.; Liu, B.; Jiang, S.; Yuan, Q.; Liu, J. Multicopper Laccase Mimicking Nanozymes with Nucleotides as Ligands. ACS Appl. Mater. Interfaces 2017, 9, 1352–1360. [Google Scholar] [CrossRef] [PubMed]
  40. Fan, W.; Lu, N.; Huang, P.; Liu, Y.; Yang, Z.; Wang, S.; Yu, G.; Liu, Y.; Hu, J.; He, Q.; et al. Glucose-Responsive Sequential Generation of Hydrogen Peroxide and Nitric Oxide for Synergistic Cancer Starving-Like/Gas Therapy. Angew. Chem. Int. Ed. 2017, 56, 1229–1233. [Google Scholar] [CrossRef] [PubMed]
  41. He, C.; Wang, J.-H.; Mao, Q.; Chen, X. Tunable Organelle Imaging by Rational Design of Carbon Dots and Utilization of Uptake Pathways. ACS Nano 2021, 15, 14465–14474. [Google Scholar]
  42. Fu, L.-H.; Wan, Y.; Qi, C.; He, J.; Li, C.; Yang, C.; Xu, H.; Lin, J.; Huang, P. Nanocatalytic Theranostics with Glutathione Depletion and Enhanced Reactive Oxygen Species Generation for Efficient Cancer Therapy. Adv. Mater. 2021, 33, 2006892. [Google Scholar] [CrossRef] [PubMed]
  43. Qin, X.; Wu, C.; Niu, D.; Qin, L.; Wang, X.; Wang, Q.; Li, Y. Peroxisome inspired hybrid enzyme nanogels for chemodynamic and photodynamic therapy. Nat. Commun. 2021, 12, 5243. [Google Scholar] [CrossRef] [PubMed]
  44. Meng, X.; Fan, H.; Chen, L.; He, J.; Hong, C.; Xie, J.; Hou, Y.; Wang, K.; Gao, X.; Gao, L.; et al. Ultrasmall metal alloy nanozymes mimicking neutrophil enzymatic cascades for tumor catalytic therapy. Nat. Commun. 2024, 15, 1626. [Google Scholar] [CrossRef] [PubMed]
  45. Zhou, Z.; Wang, Y.; Peng, F.; Meng, F.; Zha, J.; Ma, L.; Du, Y.; Peng, N.; Ma, L.; Zhang, Q.; et al. Intercalation-Activated Layered MoO3 Nanobelts as Biodegradable Nanozymes for Tumor-Specific Photo-Enhanced Catalytic Therapy. Angew. Chem. Int. Ed. 2022, 61, e202115939. [Google Scholar] [CrossRef] [PubMed]
  46. Zhong, X.; Wang, X.; Cheng, L.; Tang, Y.A.; Zhan, G.; Gong, F.; Zhang, R.; Hu, J.; Liu, Z.; Yang, X. GSH-Depleted PtCu3 Nanocages for Chemodynamic- Enhanced Sonodynamic Cancer Therapy. Adv. Funct. Mater. 2020, 30, 1907954. [Google Scholar] [CrossRef]
  47. Dong, S.; Dong, Y.; Jia, T.; Liu, S.; Liu, J.; Yang, D.; He, F.; Gai, S.; Yang, P.; Lin, J. GSH-Depleted Nanozymes with Hyperthermia-Enhanced Dual Enzyme-Mimic Activities for Tumor Nanocatalytic Therapy. Adv. Mater. 2020, 32, 2002439. [Google Scholar] [CrossRef] [PubMed]
  48. Singh, N.; Savanur, M.A.; Srivastava, S.; D’Silva, P.; Mugesh, G. A Redox Modulatory Mn3O4 Nanozyme with Multi-Enzyme Activity Provides Efficient Cytoprotection to Human Cells in a Parkinson’s Disease Model. Angew. Chem. Int. Ed. 2017, 129, 14455–14459. [Google Scholar] [CrossRef]
  49. Hu, X.; Li, F.; Xia, F.; Guo, X.; Wang, N.; Liang, L.; Yang, B.; Fan, K.; Yan, X.; Ling, D. Biodegradation-Mediated Enzymatic Activity-Tunable Molybdenum Oxide Nanourchins for Tumor-Specific Cascade Catalytic Therapy. J. Am. Chem. Soc. 2020, 142, 1636–1644. [Google Scholar] [CrossRef] [PubMed]
  50. Ge, C.; Fang, G.; Shen, X.; Chong, Y.; Wamer, W.G.; Gao, X.; Chai, Z.; Chen, C.; Yin, J.-J. Facet Energy versus Enzyme-like Activities: The Unexpected Protection of Palladium Nanocrystals against Oxidative Damage. ACS Nano 2016, 10, 10436–10445. [Google Scholar] [CrossRef] [PubMed]
  51. Xie, Y.; Wang, M.; Qian, Y.; Li, L.; Sun, Q.; Gao, M.; Li, C. Novel PdPtCu Nanozymes for Reprogramming Tumor Microenvironment to Boost Immunotherapy Through Endoplasmic Reticulum Stress and Blocking IDO-Mediated Immune Escape. Small 2023, 19, 2303596. [Google Scholar] [CrossRef] [PubMed]
  52. Zhang, A.; Gao, A.; Zhou, C.; Xue, C.; Zhang, Q.; Fuente, J.M.D.L.; Cui, D. Confining Prepared Ultrasmall Nanozymes Loading ATO for Lung Cancer Catalytic Therapy/Immunotherapy. Adv. Mater. 2023, 35, 2303722. [Google Scholar] [CrossRef] [PubMed]
  53. Zhu, P.; Pu, Y.; Wang, M.; Wu, W.; Qin, H.; Shi, J. MnOOH-Catalyzed Autoxidation of Glutathione for Reactive Oxygen Species Production and Nanocatalytic Tumor Innate Immunotherapy. J. Am. Chem. Soc. 2023, 145, 5803–5815. [Google Scholar] [CrossRef]
  54. Chen, T.; Zou, H.; Wu, X.; Liu, C.; Situ, B.; Zheng, L.; Yang, G. Nanozymatic Antioxidant System Based on MoS2 Nanosheets. ACS Appl. Mater. Interfaces 2018, 10, 12453–12462. [Google Scholar] [CrossRef]
  55. Zhang, W.; Hu, S.; Yin, J.-J.; He, W.; Lu, W.; Ma, M.; Gu, N.; Zhang, Y. Prussian Blue Nanoparticles as Multienzyme Mimetics and Reactive Oxygen Species Scavengers. J. Am. Chem. Soc. 2016, 138, 5860–5865. [Google Scholar] [CrossRef]
  56. Fu, S.; Yang, R.; Zhang, L.; Liu, W.; Du, G.; Cao, Y.; Xu, Z.; Cui, H.; Kang, Y.; Xue, P. Biomimetic CoO@AuPt nanozyme responsive to multiple tumor microenvironmental clues for augmenting chemodynamic therapy. Biomaterials 2020, 257, 120279. [Google Scholar] [CrossRef] [PubMed]
  57. Pan, M.-M.; Li, P.; Yu, Y.-P.; Jiang, M.; Yang, X.; Zhang, P.; Nie, J.; Hu, J.; Yu, X.; Xu, L. Bimetallic Ions Functionalized Metal–Organic-Framework Nanozyme for Tumor Microenvironment Regulating and Enhanced Photodynamic Therapy for Hypoxic Tumor. Adv. Healthc. Mater. 2023, 12, 2300821. [Google Scholar] [CrossRef] [PubMed]
  58. Wang, D.; Wu, H.; Wang, C.; Gu, L.; Chen, H.; Jana, D.; Feng, L.; Liu, J.; Wang, X.; Xu, P.; et al. Self-Assembled Single-Site Nanozyme for Tumor-Specific Amplified Cascade Enzymatic Therapy. Nat. Commun. 2021, 60, 3001–3007. [Google Scholar]
  59. Meng, X.; Li, D.; Chen, L.; He, H.; Wang, Q.; Hong, C.; He, J.; Gao, X.; Yang, Y.; Jiang, B.; et al. High-Performance Self-Cascade Pyrite Nanozymes for Apoptosis–Ferroptosis Synergistic Tumor Therapy. ACS Nano 2021, 15, 5735–5751. [Google Scholar] [CrossRef] [PubMed]
  60. Yang, C.; Wang, M.; Chang, M.; Yuan, M.; Zhang, W.; Tan, J.; Ding, B.; Ma, P.A.; Lin, J. Heterostructural Nanoadjuvant CuSe/CoSe2 for Potentiating Ferroptosis and Photoimmunotherapy through Intratumoral Blocked Lactate Efflux. J. Am. Chem. Soc. 2023, 145, 7205–7217. [Google Scholar] [CrossRef]
  61. Wang, Y.; Dai, X.; Wu, L.; Xiang, H.; Chen, Y.; Zhang, R. Atomic vacancies-engineered ultrathin trimetallic nanozyme with anti-inflammation and antitumor performances for intestinal disease treatment. Biomaterials 2023, 299, 122178. [Google Scholar] [CrossRef] [PubMed]
  62. Xu, C.; Lin, Y.; Wang, J.; Wu, L.; Wei, W.; Ren, J.; Qu, X. Nanoceria-triggered synergetic drug release based on CeO2-capped mesoporous silica host-guest interactions and switchable enzymatic activity and cellular effects of CeO2. Adv. Healthc. Mater. 2013, 2, 1591-9. [Google Scholar] [CrossRef] [PubMed]
  63. Gao, X.; Wang, B.; Li, J.; Niu, B.; Cao, L.; Liang, X.-J.; Zhang, J.; Jin, Y.; Yang, X. Catalytic Tunable Black Phosphorus/Ceria Nanozyme: A Versatile Oxidation Cycle Accelerator for Alleviating Cisplatin-Induced Acute Kidney Injury. Adv. Healthc. Mater. 2023, 12, 2301691. [Google Scholar] [CrossRef] [PubMed]
  64. Wang, S.; Wang, Z.; Li, Z.; Zhang, X.; Zhang, H.; Zhang, T.; Meng, X.; Sheng, F.; Hou, Y. Amelioration of systemic antitumor immune responses in cocktail therapy by immunomodulatory nanozymes. Sci. Adv. 2022, 8, eabn3883. [Google Scholar] [CrossRef] [PubMed]
  65. Biercuk, M.J.; Reilly, D.J. Solid-state spins survive. Nat. Nanotechnol. 2011, 6, 9–11. [Google Scholar] [CrossRef] [PubMed]
  66. Yang, B.; Zhang, Y.; Sun, L.; Wang, J.; Zhao, Z.; Huang, Z.; Mao, W.; Xue, R.; Chen, R.; Luo, J.; et al. Modulated Ultrasmall γ-Fe2O3 Nanocrystal Assemblies for Switchable Magnetic Resonance Imaging and Photothermal-Ferroptotic-Chemical Synergistic Cancer Therapy. Adv. Funct. Mater. 2023, 33, 2211251. [Google Scholar] [CrossRef]
  67. Wang, L.; Huo, M.; Chen, Y.; Shi, J. Iron-engineered mesoporous silica nanocatalyst with biodegradable and catalytic framework for tumor-specific therapy. Biomaterials 2018, 163, 1–13. [Google Scholar] [CrossRef] [PubMed]
  68. Mao, H.; Wen, Y.; Yu, Y.; Li, H.; Wang, J.; Sun, B. Bioinspired nanocatalytic tumor therapy by simultaneous reactive oxygen species generation enhancement and glutamine pathway-mediated glutathione depletion. J. Mater. Chem. B. 2023, 11, 131–143. [Google Scholar] [CrossRef] [PubMed]
  69. Balakrishnan, P.B.; Silvestri, N.; Fernandez-Cabada, T.; Marinaro, F.; Fernandes, S.; Fiorito, S.; Miscuglio, M.; Serantes, D.; Ruta, S.; Livesey, K.; et al. Exploiting Unique Alignment of Cobalt Ferrite Nanoparticles, Mild Hyperthermia, and Controlled Intrinsic Cobalt Toxicity for Cancer Therapy. Adv. Mater. 2020, 32, 2003712. [Google Scholar] [CrossRef] [PubMed]
  70. Lin, L.-S.; Song, J.; Song, L.; Ke, K.; Liu, Y.; Zhou, Z.; Shen, Z.; Li, J.; Yang, Z.; Tang, W.; et al. Simultaneous Fenton-like Ion Delivery and Glutathione Depletion by MnO2-Based Nanoagent to Enhance Chemodynamic Therapy. Angew. Chem. Int. Ed. 2018, 57, 4902–4906. [Google Scholar] [CrossRef] [PubMed]
  71. Tian, F.; Liu, F.; Chen, Q.; Wang, L.; Guan, S.; Zhou, S.; Chen, Y. Revealing Mn doping effect in transition metal phosphides to trigger active centers for highly efficient chemodynamic and NIR-II photothermal therapy. Chem. Eng. J. 2022, 435, 134780. [Google Scholar] [CrossRef]
  72. Xu, J.; Han, W.; Yang, P.; Jia, T.; Dong, S.; Bi, H.; Gulzar, A.; Yang, D.; Gai, S.; He, F.; et al. Tumor Microenvironment-Responsive Mesoporous MnO2-Coated Upconversion Nanoplatform for Self-Enhanced Tumor Theranostics. Adv. Funct. Mater. 2018, 28, 1803804. [Google Scholar] [CrossRef]
  73. Fan, W.; Bu, W.; Shen, B.; He, Q.; Cui, Z.; Liu, Y.; Zheng, X.; Zhao, K.; Shi, J. Intelligent MnO2 Nanosheets Anchored with Upconversion Nanoprobes for Concurrent pH-/H2O2-Responsive UCL Imaging and Oxygen-Elevated Synergetic Therapy. Adv. Mater. 2015, 27, 4155–4161. [Google Scholar] [CrossRef] [PubMed]
  74. Zhang, M.; Li, B.; Du, Y.; Zhou, G.; Tang, Y.; Shi, Y.; Zhang, B.; Xu, Z.; Huang, Q. A novel intelligent PANI/ PPy@Au@MnO2 yolk − shell nanozyme for MRI-guided ‘triple-mode’ synergistic targeted anti-tumor therapy. Chem. Eng. J. 2021, 424, 130356. [Google Scholar] [CrossRef]
  75. Xu, X.; Duan, J.; Liu, Y.; Kuang, Y.; Duan, J.; Liao, T.; Xu, Z.; Jiang, B.; Li, C. Multi-stimuli responsive hollow MnO2-based drug delivery system for magnetic resonance imaging and combined chemo-chemodynamic cancer therapy. Acta Biomater. 2021, 126, 445–462. [Google Scholar] [CrossRef] [PubMed]
  76. Xu, K.-F.; Jia, H.-R.; Zhu, Y.-X.; Liu, X.; Gao, G.; Li, Y.-H.; Wu, F.-G. Cholesterol-Modified Dendrimers for Constructing a Tumor Microenvironment-Responsive Drug Delivery System. ACS Biomater. Sci. Eng. 2019, 5, 6072–6081. [Google Scholar] [CrossRef] [PubMed]
  77. Miriyala, S.; Spasojevic, I.; Tovmasyan, A.; Salvemini, D.; Vujaskovic, Z.; St. Clair, D.; Batinic-Haberle, I. Manganese superoxide dismutase, MnSOD and its mimics. BBA Mol. Basis Dis. 2012, 1822, 794–814. [Google Scholar] [CrossRef]
  78. Yao, J.; Cheng, Y.; Zhou, M.; Zhao, S.; Lin, S.; Wang, X.; Wu, J.; Li, S.; Wei, H. ROS scavenging Mn3O4 nanozymes for in vivo anti-inflammation. Chem. Sci. 2018, 9, 2927–2933. [Google Scholar] [CrossRef] [PubMed]
  79. Huang, N.; Qian, A.; Zou, Y.; Lin, M.; Pan, W.; Chen, M.; Meng, W.; Zhang, W.; Chen, J. Immunogenic radiation therapy for enhanced anti-tumor immunity via core-shell nanocomposite-mediated multiple strategies. Theranostics 2023, 13, 4121–4137. [Google Scholar] [CrossRef] [PubMed]
  80. Zhou, M.; Tian, M.; Li, C. Copper-Based Nanomaterials for Cancer Imaging and Therapy. Bioconjugate Chem. 2016, 27, 1188–1199. [Google Scholar] [CrossRef] [PubMed]
  81. Tang, Z.; Zhang, H.; Liu, Y.; Ni, D.; Zhang, H.; Zhang, J.; Yao, Z.; He, M.; Shi, J.; Bu, W. Antiferromagnetic Pyrite as the Tumor Microenvironment-Mediated Nanoplatform for Self-Enhanced Tumor Imaging and Therapy. Adv. Mater. 2017, 29, 1701683. [Google Scholar] [CrossRef]
  82. Xiong, Q.; Liu, A.; Ren, Q.; Xue, Y.; Yu, X.; Ying, Y.; Gao, H.; Tan, H.; Zhang, Z.; Li, W.; et al. Cuprous oxide nanoparticles trigger reactive oxygen species-induced apoptosis through activation of erk-dependent autophagy in bladder cancer. Cell Death Dis. 2020, 11, 366. [Google Scholar] [CrossRef] [PubMed]
  83. Xia, L.; Wang, Y.; Chen, Y.; Yan, J.; Hao, F.; Su, X.; Zhang, C.; Xu, M. Cuprous oxide nanoparticles inhibit the growth of cervical carcinoma by inducing autophagy. Cell Death Dis. 2017, 8, 61083. [Google Scholar] [CrossRef] [PubMed]
  84. Wang, M.; Yan, Z.; Sun, M.; Feng, X.; Wang, W.; Yuan, Z. Cuprous Oxide-Based Dual Catalytic Nanostructures for Tumor Vascular Normalization-Enhanced Chemodynamic Therapy. ACS Appl. Nano Mater. 2023, 6, 6911–6919. [Google Scholar] [CrossRef]
  85. Huang, W.-C.; Lyu, L.-M.; Yang, Y.-C.; Huang, M.H. Synthesis of Cu2O Nanocrystals from Cubic to Rhombic Dodecahedral Structures and Their Comparative Photocatalytic Activity. J. Am. Chem. Soc. 2012, 134, 1261–1267. [Google Scholar] [CrossRef] [PubMed]
  86. Hu, L.; Yuan, Y.; Zhang, L.; Zhao, J.; Majeed, S.; Xu, G. Copper nanoclusters as peroxidase mimetics and their applications to H2O2 and glucose detection. Anal. Chim. Acta. 2013, 762, 83–86. [Google Scholar] [CrossRef] [PubMed]
  87. Liu, T.; Xiao, B.; Xiang, F.; Tan, J.; Chen, Z.; Zhang, X.; Wu, C.; Mao, Z.; Luo, G.; Chen, X.; et al. Ultrasmall copper-based nanoparticles for reactive oxygen species scavenging and alleviation of inflammation related diseases. Nat. Commun. 2020, 11, 2788. [Google Scholar] [CrossRef] [PubMed]
  88. Meng, X.; Zhou, K.; Qian, Y.; Liu, H.; Wang, X.; Lin, Y.; Shi, X.; Tian, Y.; Lu, Y.; Chen, Q.; et al. Hollow Cuprous Oxide@Nitrogen-Doped Carbon Nanocapsules for Cascade Chemodynamic Therapy. Small 2022, 18, 2107422. [Google Scholar] [CrossRef] [PubMed]
  89. Ma, B.; Han, J.; Zhang, K.; Jiang, Q.; Sui, Z.; Zhang, Z.; Zhao, B.; Liang, Z.; Zhang, L.; Zhang, Y. Targeted killing of tumor cells based on isoelectric point suitable nanoceria-rod with high oxygen vacancies. J. Mater. Chem. B. 2022, 10, 1410–1417. [Google Scholar] [CrossRef]
  90. Asati, A.; Santra, S.; Kaittanis, C.; Nath, S.; Perez, J.M. Oxidase-Like Activity of Polymer-Coated Cerium Oxide Nanoparticles. Angew. Chem. Int. Ed. 2009, 48, 2308–2312. [Google Scholar] [CrossRef]
  91. Mehmood, R.; Wang, X.; Koshy, P.; Yang, J.L.; Sorrell, C.C. Engineering oxygen vacancies through construction of morphology maps for bio-responsive nanoceria for osteosarcoma therapy. CrystEngComm 2018, 20, 1536–1545. [Google Scholar] [CrossRef]
  92. Xu, C.; Qu, X. Cerium oxide nanoparticle: A remarkably versatile rare earth nanomaterial for biological applications. NPG Asia Mater. 2014, 6, e90. [Google Scholar] [CrossRef]
  93. Paier, J.; Penschke, C.; Sauer, J. Oxygen Defects and Surface Chemistry of Ceria: Quantum Chemical Studies Compared to Experiment. Chem. Rev. 2013, 113, 3949–3985. [Google Scholar] [CrossRef]
  94. Cheng, X.; Huang, L.; Yang, X.; Elzatahry, A.A.; Alghamdi, A.; Deng, Y. Rational design of a stable peroxidase mimic for colorimetric detection of H2O2 and glucose: A synergistic CeO2/Zeolite Y nanocomposite. J. Colloid. Interf. Sci. 2019, 535, 425–435. [Google Scholar] [CrossRef] [PubMed]
  95. Cheng, F.; Wang, S.; Zheng, H.; Yang, S.; Zhou, L.; Liu, K.; Zhang, Q.; Zhang, H. Cu-doped cerium oxide-based nanomedicine for tumor microenvironment-stimulative chemo-chemodynamic therapy with minimal side effects. J. Colloid. Interf. Sci. 2021, 205, 111878. [Google Scholar] [CrossRef] [PubMed]
  96. Ma, B.; Zhang, K.; Sun, Z.; Pan, H.; Yang, K.; Jiang, B.; Zhao, B.; Liang, Z.; Zhang, Y.; Zhang, L. Pushpin-like nanozyme for plasmon-enhanced tumor targeted therapy. Acta Biomater. 2023, 158, 673–685. [Google Scholar] [CrossRef]
  97. Dai, X.; Zhu, Y.; Su, M.; Chen, J.; Shen, S.; Xu, C.-F.; Yang, X. Rigid Shell Decorated Nanodevice with Fe/H2O2 Supply and Glutathione Depletion Capabilities for Potentiated Ferroptosis and Synergized Immunotherapy. Adv. Funct. Mater. 2023, 33, 2215022. [Google Scholar] [CrossRef]
  98. Lei, H.; Pei, Z.; Jiang, C.; Cheng, L. Recent progress of metal-based nanomaterials with anti-tumor biological effects for enhanced cancer therapy. Exploration 2023, 3, 20220001. [Google Scholar] [CrossRef] [PubMed]
  99. Sarhan, M.; Land, W.G.; Tonnus, W.; Hugo, C.P.; Linkermann, A. Origin and Consequences of Necroinflammation. Physiol. Rev. 2018, 98, 727–780. [Google Scholar] [CrossRef] [PubMed]
  100. Wang, C.; Zhang, R.; Wei, X.; Lv, M.; Jiang, Z. Chapter Seven-Metalloimmunology: The metal ion-controlled immunity. Adv. Immunol. 2020, 145, 187–241. [Google Scholar] [PubMed]
  101. Sun, X.; Zhang, Y.; Li, J.; Park, K.S.; Han, K.; Zhou, X.; Xu, Y.; Nam, J.; Xu, J.; Shi, X.; et al. Amplifying STING activation by cyclic dinucleotide–manganese particles for local and systemic cancer metalloimmunotherapy. Nat. Nanotechnol. 2021, 16, 1260–1270. [Google Scholar] [CrossRef] [PubMed]
  102. Zhang, R.; Wang, C.; Guan, Y.; Wei, X.; Sha, M.; Yi, M.; Jing, M.; Lv, M.; Guo, W.; Xu, J.; et al. Manganese salts function as potent adjuvants. Cell Mol. Immunol. 2021, 18, 1222–1234. [Google Scholar] [CrossRef] [PubMed]
  103. Lei, H.; Li, Q.; Li, G.; Wang, T.; Lv, X.; Pei, Z.; Gao, X.; Yang, N.; Gong, F.; Yang, Y.; et al. Manganese molybdate nanodots with dual amplification of STING activation for “cycle” treatment of metalloimmunotherapy. Bioact. Mater. 2024, 31, 53–62. [Google Scholar] [CrossRef] [PubMed]
  104. Zhang, R.; Liu, C.; Zhao, R.; Du, Y.; Yang, D.; Ding, H.; Yang, G.; Gai, S.; He, F.; Yang, P. Engineering oxygen vacancy of MoOx nanozyme by Mn doping for dual-route cascaded catalysis mediated high tumor eradication. J. Colloid. Interf. Sci. 2022, 623, 155–167. [Google Scholar] [CrossRef] [PubMed]
  105. Liu, J.; Shi, X.; Qu, Y.; Wang, G. Functionalized ZnMnFe2O4–PEG–FA nanoenzymes integrating diagnosis and therapy for targeting hepatic carcinoma guided by multi-modality imaging. Nanoscale 2023, 15, 11013–11025. [Google Scholar] [CrossRef] [PubMed]
  106. Lv, W.; Cao, M.; Liu, J.; Hei, Y.; Bai, J. Tumor microenvironment-responsive nanozymes achieve photothermal-enhanced multiple catalysis against tumor hypoxia. Acta Biomater. 2021, 135, 617–627. [Google Scholar] [CrossRef] [PubMed]
  107. Lee, K.-T.; Lu, Y.-J.; Mi, F.-L.; Burnouf, T.; Wei, Y.-T.; Chiu, S.-C.; Chuang, E.-Y.; Lu, S.-Y. Catalase-Modulated Heterogeneous Fenton Reaction for Selective Cancer Cell Eradication: SnFe2O4 Nanocrystals as an Effective Reagent for Treating Lung Cancer Cells. ACS Appl. Mater. Interfaces 2017, 9, 1273–1279. [Google Scholar] [CrossRef] [PubMed]
  108. Lee, K.-T.; Liu, D.-M.; Lu, S.-Y. SnFe2O4 Nanocrystals as Highly Efficient Catalysts for Hydrogen-Peroxide Sensing. Chem. Eur. J. 2016, 22, 10877–10883. [Google Scholar] [CrossRef] [PubMed]
  109. Lee, K.-T.; Lu, S.-Y. A cost-effective, stable, magnetically recyclable photocatalyst of ultra-high organic pollutant degradation efficiency: SnFe2O4 nanocrystals from a carrier solvent assisted interfacial reaction process. J. Mater. Chem. A 2015, 3, 12259–12267. [Google Scholar] [CrossRef]
  110. Liu, F.X.; Li, T.Z. Synthesis and magnetic properties of SnFe2O4 nanoparticles. Mater. Lett. 2005, 59, 194–196. [Google Scholar] [CrossRef]
  111. Feng, L.; Liu, B.; Xie, R.; Wang, D.; Qian, C.; Zhou, W.; Liu, J.; Jana, D.; Yang, P.; Zhao, Y. An Ultrasmall SnFe2O4 Nanozyme with Endogenous Oxygen Generation and Glutathione Depletion for Synergistic Cancer Therapy. Adv. Funct. Mater. 2021, 31, 2006216. [Google Scholar] [CrossRef]
  112. Wang, Q.; Niu, D.; Shi, J.; Wang, L. A Three-in-one ZIFs-Derived CuCo(O)/GOx@PCNs Hybrid Cascade Nanozyme for Immunotherapy/Enhanced Starvation/Photothermal Therapy. ACS Appl. Mater. Interfaces 2021, 13, 11683–11695. [Google Scholar] [CrossRef] [PubMed]
  113. Fu, Y.; Zhao, X.; Zhang, J.; Li, W. DNA-Based Platinum Nanozymes for Peroxidase Mimetics. J. Phys. Chem. C 2014, 118, 18116–18125. [Google Scholar] [CrossRef]
  114. Li, X.; Yang, X.; Cheng, X.; Zhao, Y.; Luo, W.; Elzatahry, A.A.; Alghamdi, A.; He, X.; Su, J.; Deng, Y. Highly dispersed Pt nanoparticles on ultrasmall EMT zeolite: A peroxidase-mimic nanoenzyme for detection of H2O2 or glucose. J. Colloid. Interf. Sci. 2020, 570, 300–311. [Google Scholar] [CrossRef] [PubMed]
  115. Gao, Z.; Xu, M.; Hou, L.; Chen, G.; Tang, D. Irregular-shaped platinum nanoparticles as peroxidase mimics for highly efficient colorimetric immunoassay. Anal. Chim. Acta 2013, 776, 79–86. [Google Scholar] [CrossRef] [PubMed]
  116. Higuchi, A.; Siao, Y.-D.; Yang, S.-T.; Hsieh, P.-V.; Fukushima, H.; Chang, Y.; Ruaan, R.-C.; Chen, W.-Y. Preparation of a DNA Aptamer−Pt Complex and Its Use in the Colorimetric Sensing of Thrombin and Anti-Thrombin Antibodies. Anal. Chem. 2008, 80, 6580–6586. [Google Scholar] [CrossRef] [PubMed]
  117. Peng, F.F.; Zhang, Y.; Gu, N. Size-dependent peroxidase-like catalytic activity of Fe3O4 nanoparticles. Chin. Chem. Lett. 2008, 19, 730–733. [Google Scholar] [CrossRef]
  118. Liu, B.; Liu, J. Surface modification of nanozymes. Nano Res. 2017, 10, 1125–1148. [Google Scholar] [CrossRef]
  119. Dutta, S.; Corni, S.; Brancolini, G. Molecular Dynamics Simulations of a Catalytic Multivalent Peptide–Nanoparticle Complex. Int. J. Mol. Sci. 2021, 22, 3624. [Google Scholar] [CrossRef] [PubMed]
  120. Kyrychenko, A.; Blazhynska, M.M.; Kalugin, O.N. Protonation-dependent adsorption of polyarginine onto silver nanoparticles. J. Appl. Phys. 2020, 127, 075502. [Google Scholar] [CrossRef]
  121. Power, D.; Rouse, I.; Poggio, S.; Brandt, E.; Lopez, H.; Lyubartsev, A.; Lobaskin, V. A multiscale model of protein adsorption on a nanoparticle surface. Model. Simul. Mater. Sci. 2019, 27, 084003. [Google Scholar] [CrossRef]
  122. Tavanti, F.; Pedone, A.; Menziani, M.C. Multiscale Molecular Dynamics Simulation of Multiple Protein Adsorption on Gold Nanoparticles. Model. Simul. Mater. Sci. Eng. 2019, 20, 3539. [Google Scholar] [CrossRef] [PubMed]
Figure 1. Summary of this review: enzymatic activities of TMO−based nanozymes and corresponding transition metal ions. POD: peroxidase, CAT: catalase, GSH−OXD: glutathione oxidase, SOD: superoxide dismutase.
Figure 1. Summary of this review: enzymatic activities of TMO−based nanozymes and corresponding transition metal ions. POD: peroxidase, CAT: catalase, GSH−OXD: glutathione oxidase, SOD: superoxide dismutase.
Materials 17 02896 g001
Figure 2. (a) Schematic illustration to indicate the synthetic procedure of hollow PBCTER nanozymes. (b) POD–mimicking–activity–related Michaelis–Menten kinetic analysis of PBCTER nanozymes [51]. (c) Therapy mechanism of AP-HAI nanoprobes in vivo. (d) Schematic demonstrating the peroxidase-mimicking activities of AP-H nanozymes. (e) Michaelis–Menten kinetic study of AP-H with H2O2 as substrate [52].
Figure 2. (a) Schematic illustration to indicate the synthetic procedure of hollow PBCTER nanozymes. (b) POD–mimicking–activity–related Michaelis–Menten kinetic analysis of PBCTER nanozymes [51]. (c) Therapy mechanism of AP-HAI nanoprobes in vivo. (d) Schematic demonstrating the peroxidase-mimicking activities of AP-H nanozymes. (e) Michaelis–Menten kinetic study of AP-H with H2O2 as substrate [52].
Materials 17 02896 g002
Figure 3. (a) Schematic illustration to indicate the synthetic procedure of hollow CoO@AuPt NPs. (b) A notable elevation of dissolved O2 levels was observed in less than 3 min, and the O2 generation rate exhibited an insignificant correlation with acidity [56]. (c) The fabrication process of ZMRPC@HA. (d) O2 generation after treatment with ZMRP of 0−80 μg/mL in the presence of 10 mm H2O2 [57].
Figure 3. (a) Schematic illustration to indicate the synthetic procedure of hollow CoO@AuPt NPs. (b) A notable elevation of dissolved O2 levels was observed in less than 3 min, and the O2 generation rate exhibited an insignificant correlation with acidity [56]. (c) The fabrication process of ZMRPC@HA. (d) O2 generation after treatment with ZMRP of 0−80 μg/mL in the presence of 10 mm H2O2 [57].
Materials 17 02896 g003
Figure 4. (a) Schematic illustration of the self-cascade pyrite nanozymes with ultrahigh POD-like catalytic activity and intrinsic GSH–OXD–mimicking ability for apoptosis−ferroptosis synergistic tumor therapy. (b) Kinetic assay for the GSH-OXD-like activity of pyrite nanozymes with GSH as substrate. (c) Reduction in GSH in an air, O2, and N2 atmosphere, respectively [59]. (d) The mechanism of potentiating antitumor immunotherapy induced by TME and NIR coactivatable synergistic PTT/PCT/Ferroptosis and improved by LA metabolic reprogramming of CSC@Syro. (e) GSH-OXD-like activity of CSC [60].
Figure 4. (a) Schematic illustration of the self-cascade pyrite nanozymes with ultrahigh POD-like catalytic activity and intrinsic GSH–OXD–mimicking ability for apoptosis−ferroptosis synergistic tumor therapy. (b) Kinetic assay for the GSH-OXD-like activity of pyrite nanozymes with GSH as substrate. (c) Reduction in GSH in an air, O2, and N2 atmosphere, respectively [59]. (d) The mechanism of potentiating antitumor immunotherapy induced by TME and NIR coactivatable synergistic PTT/PCT/Ferroptosis and improved by LA metabolic reprogramming of CSC@Syro. (e) GSH-OXD-like activity of CSC [60].
Materials 17 02896 g004
Figure 5. (a) Schematic illustration of the fabrication of TMNSs. (b,c) Scheme of TMNSs as multifunctional nanozyme−based nanoplatforms with RONS scavenging and photothermal conversion performance for colon disease treatment. (d) SOD−like activity of TMNSs. (e) O2 generation ability of TMNSs in the presence of H2O2 solution [61].
Figure 5. (a) Schematic illustration of the fabrication of TMNSs. (b,c) Scheme of TMNSs as multifunctional nanozyme−based nanoplatforms with RONS scavenging and photothermal conversion performance for colon disease treatment. (d) SOD−like activity of TMNSs. (e) O2 generation ability of TMNSs in the presence of H2O2 solution [61].
Materials 17 02896 g005
Figure 6. (a) Production of UF@PPDF NPs with assembled ultra–small γ–Fe2O3 nanocrystals, loaded with the chemotherapeutic drug Dox and cancer cell targeting molecules. (b) The mechanism of the UF@PPDF NPs for PTT–chemotherapy–ferroptosis trifunctional synergistic cancer therapy. (c) EPR spectra demonstrating •OH generation by UF@PPDF NPs, with 5,5-dimethyl-1-pyrroline-Noxide (DMPO) serving as the •OH trapping agent. (d) Changes in UV-Vis spectra showing MB degradation in different systems. (e) Time–dependent GSH depletion by UF@PPDF NPs, with DTNB as the trapping agent [66]. (f) A visual representation of the therapeutic effectiveness of rFeOx–HMSN nanocatalysts. An analysis of the relationship between the initial velocity of hydroxyl radical generation and H2O2 concentration by using Michaelis–Menten fitting curves, with TMB concentrations of 0.8 mM and 1.6 mM, is shown in (g,h), respectively. (i) The absorbance of TMB aqueous solution under acidic conditions (pH = 6.0) with the addition of rFeOx–HMSN and H2O2, as well as H2O2 alone. (j) The in vivo T2–weighted MR imaging of mice bearing 4T1 tumors before and after the intravenous administration of PEG/rFeOx–HMSN nanocatalyst over a prolonged period of time [67].
Figure 6. (a) Production of UF@PPDF NPs with assembled ultra–small γ–Fe2O3 nanocrystals, loaded with the chemotherapeutic drug Dox and cancer cell targeting molecules. (b) The mechanism of the UF@PPDF NPs for PTT–chemotherapy–ferroptosis trifunctional synergistic cancer therapy. (c) EPR spectra demonstrating •OH generation by UF@PPDF NPs, with 5,5-dimethyl-1-pyrroline-Noxide (DMPO) serving as the •OH trapping agent. (d) Changes in UV-Vis spectra showing MB degradation in different systems. (e) Time–dependent GSH depletion by UF@PPDF NPs, with DTNB as the trapping agent [66]. (f) A visual representation of the therapeutic effectiveness of rFeOx–HMSN nanocatalysts. An analysis of the relationship between the initial velocity of hydroxyl radical generation and H2O2 concentration by using Michaelis–Menten fitting curves, with TMB concentrations of 0.8 mM and 1.6 mM, is shown in (g,h), respectively. (i) The absorbance of TMB aqueous solution under acidic conditions (pH = 6.0) with the addition of rFeOx–HMSN and H2O2, as well as H2O2 alone. (j) The in vivo T2–weighted MR imaging of mice bearing 4T1 tumors before and after the intravenous administration of PEG/rFeOx–HMSN nanocatalyst over a prolonged period of time [67].
Materials 17 02896 g006
Figure 8. (a) The formation process of HCONC. (b) HCONC-catalyzed cascade reaction for CDT. (c,d) The catalytic kinetics of HCONC and SCONC were studied under neutral and acidic conditions at room temperature, and their steady–state behavior was noted. (e) The relationship between the activity of •OH generation and the concentration of H2O2 in the presence of HCONC or SCONC was analyzed using Michaelis–Menten fitting curves [88].
Figure 8. (a) The formation process of HCONC. (b) HCONC-catalyzed cascade reaction for CDT. (c,d) The catalytic kinetics of HCONC and SCONC were studied under neutral and acidic conditions at room temperature, and their steady–state behavior was noted. (e) The relationship between the activity of •OH generation and the concentration of H2O2 in the presence of HCONC or SCONC was analyzed using Michaelis–Menten fitting curves [88].
Materials 17 02896 g008
Figure 9. (a) Schematic illustration of CCC NPs for synergistic cancer therapy. (b) Quantitative analysis of the residue H2O2 in the solution after the application of M–CeO2 NPs under physiological pH conditions. (c) The absorption spectra of the H2O2 indicator [Ti(SO4)2] solution [95].
Figure 9. (a) Schematic illustration of CCC NPs for synergistic cancer therapy. (b) Quantitative analysis of the residue H2O2 in the solution after the application of M–CeO2 NPs under physiological pH conditions. (c) The absorption spectra of the H2O2 indicator [Ti(SO4)2] solution [95].
Materials 17 02896 g009
Table 1. Typical examples of nanozymes with multienzymatic activities for enhancing tumor therapy.
Table 1. Typical examples of nanozymes with multienzymatic activities for enhancing tumor therapy.
NanozymeTransition Metal IonsEnzymatic ActivityApplicationsTarget TissueType of StudyTypes of CellTypes of ModelReferences
DMSN-Au-Fe3O4-CB839FeGOx, PODFenton-like reactions, CDTSubcutaneous tumorin vitro/in vivo4T1BALB/c mice[68]
rFeOx-HMSNFePODFenton-like reactions, T2-MRISubcutaneous tumorin vitro/in vivo4T1Nude mice[67]
UF@PPDFFePOD, GSH-OXDT1-weighted MRI, photothermal ferroptotic chemical synergistic cancer therapySubcutaneous tumorin vitro/in vivoHeLaBALB/c mice[66]
Ce6/MnO2@DPC NPsMnCATEnhanced PDTSubcutaneous tumorin vitro/in vivoU14Nude mice[76]
MS@MnO2MnPODMRI-monitored chemodynamic combination therapyIn situ implanted tumorin vitro/in vivoU87MGNude mice[70]
UiO@Mn3O4@PAAMnCAT, POD, GSH-OXDImprove the efficacy of immunogenic RT by priming strong ICDSubcutaneous tumorin vitro/in vivo4T1BALB/c mice[79]
Mn3O4 NPsMnCAT, SODTreating ROS-related diseases/in vitro/in vivoHeLaKunming mice[78]
Cu5.4O USNPsCuCAT, SOD, GSH-OXDAgainst ROS-mediated damage/in vitro/in vivoHEK293BALB/c mice[87]
Au/CeO2CeOXD, PODSuperior antitumor effects both in vitro and in vivoSubcutaneous tumorin vitro/in vivoSMMC-7721BALB/c nude
mice
[96]
Cu-CeO2 NPsCeCAT, PODEffective breast cancer therapySubcutaneous tumorin vitro/in vivoMDA-MB-231Nude mice[95]
Cu2O@DexCuPODEnhanced CDTSubcutaneous tumorin vitro/in vivoHepG2ICR mice[84]
Cu2OCuPOD, GSH-OXDFenton-like reaction, CDT/in vitroAGS/MKN45/[88]
ZnMnFe2O4Zn, Mn, FePOD,Synergistic tumor cell diagnosis and ablationSubcutaneous tumorin vitro/in vivoHepG2Nude mice[104]
MnMoOxMn, MoPOD, GSH-OXDAntitumor metalloimmunotherapySubcutaneous tumorin vitro/in vivoCT26BALB/c[103]
SnFe2O4Sn, FePOD, GSH-OXD, CATImaging-guided synergetic CDT/PTT/PDT.Subcutaneous tumorin vitro/in vivo4T1BALB/c nude[111]
CuMnOxCu, MnPOD, GSH-OXD, CAT, OXDPhotothermally enhanced multiple catalysis against tumor hypoxiaSubcutaneous tumorin vitro/in vivoHeLaKunming mice[106]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Sun, H.; Bai, Y.; Zhao, D.; Wang, J.; Qiu, L. Transition-Metal-Oxide-Based Nanozymes for Antitumor Applications. Materials 2024, 17, 2896. https://doi.org/10.3390/ma17122896

AMA Style

Sun H, Bai Y, Zhao D, Wang J, Qiu L. Transition-Metal-Oxide-Based Nanozymes for Antitumor Applications. Materials. 2024; 17(12):2896. https://doi.org/10.3390/ma17122896

Chicago/Turabian Style

Sun, Huilin, Yang Bai, Donghui Zhao, Jianhao Wang, and Lin Qiu. 2024. "Transition-Metal-Oxide-Based Nanozymes for Antitumor Applications" Materials 17, no. 12: 2896. https://doi.org/10.3390/ma17122896

APA Style

Sun, H., Bai, Y., Zhao, D., Wang, J., & Qiu, L. (2024). Transition-Metal-Oxide-Based Nanozymes for Antitumor Applications. Materials, 17(12), 2896. https://doi.org/10.3390/ma17122896

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop